has been cited by the following article(s):
[1]
|
Dual anti-PD-(L)1/TGF-β inhibitors in cancer immunotherapy – Updated
International Immunopharmacology,
2023
DOI:10.1016/j.intimp.2023.110648
|
|
|
[2]
|
Dual anti-PD-(L)1/TGF-β inhibitors in cancer immunotherapy – Updated
International Immunopharmacology,
2023
DOI:10.1016/j.intimp.2023.110648
|
|
|
[3]
|
Dual anti-PD-(L)1/TGF-β inhibitors in cancer immunotherapy – Updated
International Immunopharmacology,
2023
DOI:10.1016/j.intimp.2023.110648
|
|
|